Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK

PLoS One. 2020 Feb 25;15(2):e0229224. doi: 10.1371/journal.pone.0229224. eCollection 2020.

Abstract

Background: The current UK vaccination programme for herpes zoster (HZ) excludes people aged ≥80 years. This study aimed to quantify the number of individuals ≥80 years who missed HZ vaccination and the consequent epidemiological and economic burden of HZ and post-herpetic neuralgia (PHN).

Methods: Immunocompetent individuals aged ≥80 years between 1st September 2013 and 31st December 2017 in the Clinical Practice Research Datalink were selected and linked to Hospital Episodes Statistics, where available. Rates of HZ and PHN and healthcare resource utilisation were investigated for the overall study population and by age group (80-84, 85-89, ≥90 years old) and the burden of HZ and PHN was projected to the UK population.

Results: 4,858 HZ episodes and 464 PHN cases were identified in 255,165 individuals over 576,421 person-years (PY). Rates of HZ and PHN were 8.43 (95% confidence interval [CI] 8.19-8.66) and 0.80 (0.73-0.87) per 1,000 PY respectively and lowest in those aged ≥90 (HZ rate 7.37/1,000 PY; PHN rate 0.56/1,000 PY). Within HZ episodes, 10.27% of GP visits, 5.82% of prescribed medications and 21.65% of hospitalisations were related to HZ/PHN. Median length of hospitalisation increased from 7.0 days for all-cause to 10.5 days for HZ/PHN related hospitalisations. Individuals ≥90 stayed in hospital a median of 3-4 days longer than younger groups. Approximately 2.23 million individuals in the UK missed HZ vaccination since 2013 (1.86 million had never been eligible and 365,000 lost eligibility for HZ vaccination), resulting in an estimated 43,149 HZ episodes.

Conclusion: This study highlights the impact of the 80-year upper age limit policy on the health system. Our study estimates that 2.23 million individuals in the UK may have lost the opportunity to be vaccinated and that their burden of HZ and PHN remains high, especially among the very elderly.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged, 80 and over
  • Female
  • Follow-Up Studies
  • Health Care Costs
  • Health Services / economics
  • Health Services / statistics & numerical data*
  • Herpes Zoster / economics*
  • Herpes Zoster / epidemiology*
  • Herpesvirus 3, Human / isolation & purification
  • Hospitalization / economics
  • Hospitalization / statistics & numerical data*
  • Humans
  • Incidence
  • Male
  • Neuralgia, Postherpetic / economics*
  • Neuralgia, Postherpetic / epidemiology*
  • Prognosis
  • Retrospective Studies
  • United Kingdom / epidemiology

Grants and funding

This work was sponsored and funded by Merck Sharp & Dohme Ltd, UK. IM, BG and YP were employees of Merck Sharp & Dohme Ltd. BN received consultancy fees from Merck Sharp & Dohme Ltd, UK. MD, NQ and VP were employed by OXON Epidemiology Ltd which received funds from Merck Sharp & Dohme Ltd, UK to conduct the study. The funder provided support in the form of salaries for authors IM, BQ and YP and approved the study design for scientific integrity but did not have any additional role in the data collection and analysis, decision to publish or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.